CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 52 enrolled
Drug / intervention
HFA MDI +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05850494
NCT05850494Phase 3Completed
CompareCT.gov

Randomized, DB, Crossover Study to Assess Bronchospasm Potentially Induced by HFO MDI vs. HFA MDI Propellant in Participants With Asthma Well/Partially Controlled on SABA With or Without Low-Dose ICS

AstraZeneca·interventional·Posted May 9, 2023·Updated Feb 6, 2026

In Brief

A Phase 3 clinical trial evaluating HFA MDI and HFO MDI for Asthma. Completed, enrolled 52 participants across 4 sites.

Detailed Summary

A study to assess bronchospasm potentially induced by HFO MDI as compared with HFA MDI in participants with well controlled or partially controlled asthma

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
202420252026
First PostedMay 9, 2023
Enrollment StartMay 2, 2023
Primary CompletionAug 21, 2023
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 3.1 years ago

Interventions

HFA MDIdrug

* Dose formulation: MDI * Unit dose strength(s): Reference (propellant only) * Dosage Level: 4 inhalations, single dose * Route of administration: Oral inhalation * Participants will receive treatment A in 1 or 2 possible sequences AB or BA

HFO MDIdrug

* Dose formulation: MDI * Unit dose strength(s): Experimental (propellant only) * Dosage Level: 4 inhalations, single dose * Route of administration: Oral inhalation * Participants will receive treatment A in 1 or 2 possible sequences AB or BA